Skip to content

Clonal Hematopoiesis, Somatic and Post-Zygotic Mosaicism in Multigene Cancer Testing for Geneticists

ACMG 2026 dedicated symposium on the clinical-lab translation of population-scale CHIP and mosaicism findings into multigene hereditary-cancer panel testing — incidental-finding handling, reporting thresholds, and germline-vs-clonal disambiguation.

  • Speaker / institution: Symposium panel — clinical-lab CHIP working-group representatives, Bick-aligned and Natarajan-aligned investigator pool, hereditary-cancer panel lab medical directors (Ambry / GeneDx / Color / Invitae-successor labs); specific speaker slate TBC from GIM supplement
  • Anchor type: methods + clinical
  • Day / session: Mid-meeting symposium (Day 3–4, Mar 12–13, 2026); exact slot TBD
  • Status: post-meeting; from ACMG meeting site featured-session listing; speaker slate and concrete reporting recommendations TBD pending GIM supplement and Digital Edition

Headline finding

Multigene cancer panels run on blood DNA routinely surface variants in genes (DNMT3A, TET2, ASXL1, TP53, PPM1D, CHEK2, JAK2, ATM, others) at non-germline variant allele fractions — clonal hematopoiesis of indeterminate potential (CHIP) — alongside post-zygotic mosaic variants that are biologically distinct from CHIP but operationally hard to distinguish in a clinical lab. The symposium frames the reporting decision tree: when is a sub-50% VAF call CHIP (don't report as germline), when is it post-zygotic mosaicism (report with caveat), and when is it germline-with-allelic-imbalance. Cohort numerics from contributing labs (CHIP detection rates in hereditary-cancer panel submissions, age-stratified prevalence, downstream MN-risk follow-up) TBD pending supplement.

Methodology / framework

Operational framework combining: (1) VAF distribution analysis with tissue-comparator (buccal / fibroblast / skin) when available; (2) gene-list stratification (canonical CHIP drivers vs hereditary-cancer-syndrome genes with CHIP overlap, particularly TP53, CHEK2, ATM); (3) deeper sequencing of borderline VAFs; (4) longitudinal resampling for suspected clonal expansion. ACMG/AMP framework adaptation: PM6 / PS2 cannot apply to clonal events; PM2 / BS1 frequency thresholds need clonal-event-aware modification.

Lab-translation deep dive

Validation requirements. Disambiguating CHIP from post-zygotic mosaicism vs germline-with-allelic-imbalance requires the lab to validate (a) VAF accuracy at low fractions (10–40%) with replicate variance characterized, (b) sensitivity of variant callers at sub-50% VAF on hereditary-cancer-panel coverage depths (typically 300–500x), and (c) a tissue-comparator workflow (buccal swab, cultured fibroblast, or skin punch) with its own end-to-end validation. Many existing hereditary-cancer panels were validated only for germline (~50% / ~100% VAF expectations) — extension to clonal calls is a net-new analytical-validation event.

Lab-stack changes. Operational additions: reflex tissue-comparator collection workflow (logistics + consent), deeper sequencing for borderline VAFs, longitudinal resampling at defined intervals (6–12 months) for suspected clonal expansion, and pipeline-level flags that block germline-style reporting on canonical CHIP-driver variants (DNMT3A, TET2, ASXL1, PPM1D, JAK2). LIMS schema needs a clonal-status field per variant.

Regulatory / insurance. No CAP-checklist requirement specific to CHIP disambiguation as of 2026 (TBD pending symposium recommendations and ACMG Practice Resources). Payer coverage for reflex tissue-comparator testing is patchwork — typically billed against the hereditary-cancer-panel CPT code rather than separately. Insurance implications of incidental CHIP reporting (life / long-term-care underwriting) are an emerging ELSI question.

Variant curation. ACMG/AMP framework modifications required: PM6 / PS2 (de novo) cannot apply to clonal events; PM2 / BS1 (population frequency) needs clonal-event-aware thresholds; functional-evidence interpretation (PS3 / BS3) must consider clonal-selection bias. Gene-specific guidance for TP53 / CHEK2 / ATM (overlap genes) is the highest-leverage curation deliverable from this symposium.

Where it fits in the corpus

  • ASH 2026: clinical sequelae — CHIP → CCUS → MDS / AML progression; same investigator pool with the outcomes framing
  • ASHG 2026: population-scale CHIP statistical-genetics talks (Bick / Natarajan / Jaiswal-aligned)
  • AACR 2026: germline-somatic integration and therapy-related MN sessions inherit the CHIP-disambiguation framing
  • ASCO 2026: therapy-related MN risk in cancer survivors with CHIP at baseline

Open questions

  • Should clinical hereditary-cancer-panel reports include a CHIP-status section as standard?
  • TP53 / CHEK2 sub-50% VAF: germline-mosaic vs CHIP — what tissue panel does a lab actually run?
  • Patient counseling for incidental CHIP — who owns the longitudinal MN-risk follow-up?

Sources